Home Featured

Featured

Random

Psychedelics Take a Step Towards the Policy Agenda in Czechia

Breaking: Lykos Therapeutics Moved to Patent MDMA In Late 2022, Filing Reveals

Gut Feeling: Links Between LSD, Endocannabinoids, and the Microbiome

Bright Minds Biosciences Strengthens Scientific Advisory Team to Prepare for Future Growth

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Mindset Pharma Files National Patents Protecting Family 1 Application in 16...

Field Trip Health Ltd. Announces Completion of DMPK Studies, Engineering Batch...

Free Webinar – NueLife: Empowering Patients with At-Home Ketamine Therapy

Psychedelics and Perception Part 1: The First Era of Research

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical...

PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the...

Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel

Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results...

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

TRYP THERAPEUTICS INC. ANNOUNCES BOARD CHANGES AND CLOSING OF FIRST TRANCHE...

12 3...311 Page 1 of 311

EDITOR PICKS

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.